Anti-MMP9, Anti-Menke's Disease, and Anti-Wilson's Disease mAbs

Tech ID: 11226 / UC Case 2007-636-0

Abstract

Monoclonal Antibodies Against MMP9, Menke's Disease, and Wilson's Disease

Full Description

A researcher at the University of California, Davis has developed the following monoclonal antibodies (mAbs), which are being made available for bailment as tangible research property:

    L51/57, L51/73, L51/80 and L51/82
    • Anti-MMP9 matrix metalloproteinase mAbs
    L60/4
    • Anti-Menke's disease protein/Cu2+ transporting ATPase protein mAb
    L62/29
    • Anti-Wilson's disease protein/Cu2+ transporting ATPase ß protein mAb

A more detailed description of each clone can be found by searching the Neuromab Catalog (see www.neuromab.org).

Suggested uses

These mAbs can be used to recognize their respective endogenous target proteins in tissue as well as the recombinant proteins for MMP9 matrix metalloproteinase 9, Menke's disease, and Wilson's disease.

Features/Benefits

L60/4 and L62/29 are the first anti-Menke's disease protein/Cu2+ transporting ATPase protein mAb and anti-Wilson's disease protein/Cu2+ transporting ATPase ß protein mAb, respectively. 

Contact

Learn About UC TechAlerts - Save Searches and receive new technology matches

Inventors

  • Trimmer, James S.

Other Information

Keywords

monoclonal antibodies, mAbs, L60/4, L62/29, L51/57, L51/73, L51/80, L51/82, Wilson's disease, Menke's disease, MMP-9, MMP9, matrix metalloproteinase, MMP9 matrix metalloproteinase, L63/22, GPR49

Categorized As